Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Mar 3;41(10):1657-1667.
doi: 10.1016/j.vaccine.2023.01.048. Epub 2023 Feb 4.

Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study

Rahsan Erdem  1 , Ilse De Coster  2 , Kanchanamala Withanage  3 , Laina D Mercer  1 , Arnaud Marchant  4 , Martin Taton  4 , Nathalie Cools  5 , Eva Lion  5 , Fred Cassels  1 , Deborah Higgins  1 , Karen Ivinson  1 , Emily Locke  1 , Kutub Mahmood  1 , Peter F Wright  6 , Chris Gast  1 , Jessica A White  1 , Margaret E Ackerman  6 , Jennifer L Konopka-Anstadt  7 , Bernardo A Mainou  7 , Pierre Van Damme  3
Affiliations
Clinical Trial

Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study

Rahsan Erdem et al. Vaccine. .

Abstract

Background: Inactivated trivalent poliovirus vaccine (IPV) induces humoral immunity, which protects against paralytic poliomyelitis but does not induce sufficient mucosal immunity to block intestinal infection. We assessed the intestinal immunity in healthy adults in Belgium conferred by a co-formulation of IPV with the mucosal adjuvant double mutant Labile Toxin (dmLT) derived from Escherichia coli.

Methods: Healthy fully IPV-vaccinated 18-45-year-olds were randomly allocated to three groups: on Day 1 two groups received one full dose of IPV (n = 30) or IPV + dmLT (n = 30) in a blinded manner, and the third received an open-label dose of bivalent live oral polio vaccine (bOPV types 1 and 3, n = 20). All groups received a challenge dose of bOPV on Day 29. Participants reported solicited and unsolicited adverse events (AE) using study diaries. Mucosal immune responses were measured by fecal neutralization and IgA on Days 29 and 43, with fecal shedding of challenge viruses measured for 28 days. Humoral responses were measured by serum neutralizing antibody (NAb).

Results: Solicited and unsolicited AEs were mainly mild-to-moderate and transient in all groups, with no meaningful differences in rates between groups. Fecal shedding of challenge viruses in both IPV groups exceeded that of the bOPV group but was not different between IPV and IPV + dmLT groups. High serum NAb responses were observed in both IPV groups, alongside modest levels of fecal neutralization and IgA.

Conclusions: Addition of dmLT to IPV administered intramuscularly neither affected humoral nor intestinal immunity nor decreased fecal virus shedding following bOPV challenge. The tolerability of the dose of dmLT used in this study may allow higher doses to be investigated for impact on mucosal immunity. Registered on ClinicalTrials.gov - NCT04232943.

Keywords: Poliovirus; dmLT; inactivated poliovirus vaccine (IPV); intestinal immunity; vaccine.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Study flow chart.
Fig. 2
Fig. 2
Frequencies of solicited local reactions and systemic adverse events in the study groups for 7 days after vaccination on Day 1.
Fig. 3
Fig. 3
Shedding of poliovirus types 1 and 3 over the 28 days after challenge with bOPV in the three study groups. Shown as percentages of each group shedding with 95% CI bars.
Fig. 4
Fig. 4
Presence of fecal type-specific poliovirus neutralization activity in the three study groups. Shown as percentages of each group with detected activity with 95% CI bars.
See this image and copyright information in PMC

References

    1. Chard A., Dataa S., Tallis G., et al. Progress toward polio eradication – Worldwide, January 2018 – March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(25):784–789. - PMC - PubMed
    1. WHO. Polio Case Count. <https://extranet.who.int/polis/public/CaseCount.aspx> [accessed December 7, 2022].
    1. Kew O., Sutter R.W., de Gourville E.M., et al. Vaccine-derived polioviruses and the Endgame Strategy for Global Polio Eradication. Ann Rev Microbiol. 2005;59:587–635. - PubMed
    1. Hampton L., Farrell M., Ramirez-Gonzalez A., et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine – worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(35):934–938. - PubMed
    1. Crothers J.W., Colgate E.R., Cowan K.J., et al. Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial. Vaccine. 2022;40:2705–2713. - PMC - PubMed

Publication types

Associated data